Biofabri of Zendal Group has been selected by the CEPI as a strategic facility to increase the manufacturing capacity of Covid-19 vaccines at an international scale

  • The CEPI (Coalition for Epidemic Preparedness Innovations) is an international partnership founded in 2017 to spur development of vaccines that prevent future epidemics
  • The agreement signed between Biofabri of Zendal Group and the CEPI lays down that the biopharmaceutical company will reserve a manufacturing capacity of at least 500 million Covid-19 vaccine doses
  • Zendal, through its subsidiary Biofabri, is the first company selected by the CEPI in Europe in the acceleration process for the vaccine against Covid-19
  • The CEPI aims to produce 2 thousand million safe and effective doses of the vaccine against Covid-19 by the end of 2021

Porriño (Spain), the 21th of October 2020. Zendal Group pushes forward with its biotechnological efforts in the fight against Covid-19. This was confirmed after the recently signed agreement with the CEPI (Coalition for Epidemic Preparedness Innovations), which cements this worldwide partnership that hopes to produce 2 thousand million safe and effective doses of the vaccine against Covid-19 by the end of 2021. The global distribution will be carried out through the COVAX Fund, an international initiative that aims to ensure equal access to Covid-19 vaccines for all participating countries.

This agreement establishes that the Spanish company, the first and only one selected until now in the EU by the CEPI, will reserve part of its manufacturing capacity for Covid-19 vaccines. Thus, Zendal Group’s role in scientific and technological advances that they are developing at an international level in the fight against SARS-COV-2 is further strengthened.

Under this agreement, Zendal, through its subsidiary Biofabri, will reserve the manufacturing capacity (fill/finish) of COVID-19 vaccines that the CEPI develops until May 2022. The estimated capacity could exceed the 500 million vaccine doses with an option to increase this reserve.

For Zendal it is the second big step in the development work the company has done in the fight against SARS-COV-2, since as already announced last month, it will be in charge of manufacturing the vaccine antigen of the American multinational Novavax, for the EU, until now being the first Spanish company authorised to manufacture the vaccine against COVID.

For Andrés Fernández, the CEO of Zendal: “This recently signed agreement with CEPI, of key importance in these moments, highlights the necessity for many stakeholders to collaborate in the struggle against the pandemic.

This also strengthens the position of Zendal as a biotechnology group qualified and capable of carrying out the entire production process of a vaccine, from the production of bulk antigen to the fill and finish for its eventual placing in the market. For us, this and other Covid projects in which we are involved, imply endorsement of the work developed over many years by our team in the field of biotechnology and vaccines”.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated 9 partnerships to develop vaccines against the novel coronavirus. The programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.

Before the emergence of COVID-19 CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).

It is a public-private partnership that counts on finance and/or support from different countries worldwide such as Japan, to which Spain has joined this year with a contribution of 75 million euros; international organisms such as the WHO or UNICEF and foundations such as Bill and Melinda Gates Foundation.

The role of COVAX

COVAX, the backbone of immunisation for the Accelerator for access to the mechanisms against COVID-19, a partnership created in 2020 to set up the necessary means to accelerate the search for the vaccine. It is co-directed by the Coalition for the Promotion of Innovations in pursuit of Preparation against Epidemics (CEPI), the Alliance for Vaccines (Gavi) and the World Health Organization (WHO), in collaboration with vaccine manufacturers of developed and developing countries. It is the only worldwide initiative that works with governments (currently 172) and the main manufacturers to guarantee that the vaccines against COVID-19 are available to all the world both for affluent and lower income countries.

Compartir: